Blog

Alzheimer’s is a disease, very much like cancer, that affects so many of us, if not directly then through the experience of a family member or friend. There are currently 5 million people in the US living with Alzheimer’s and given that the western population experiences increasingly longer life, it’s predicted that by 2050 this […]

A story in the UK press on 21 November 2017, Cancer tests in supermarket car parks in bid to boost detection rates, elicited the comment from Diaceutics of “Now that’s progress!” Our vision is that better testing leads to better patient outcomes and earlier diagnosis in the patient journey is a big part of that. […]

If you’re going to take part in a charity cycle race for cancer, then where better than California? This was the sunny setting for Ewelina Golebiewska and John McNamara from Diaceutics as they joined Team Pfizer in November 2017 on the two-day Padres Pedal the Cause event. “The scenery was amazing and the atmosphere even better, […]

If you’ve ever had a blood test or a biopsy and questioned the time it takes to receive the results, the answer could be because the process involved can be more complex than you’d imagine, especially when a sample requires testing not once, but up to four times. Even though the range of diagnostic tests […]

Precision or personalized medicine is taking us into an era of unprecedented breakthroughs in patient treatment and its progress depends to a great extent upon the best possible diagnostic testing. Optimizing test implementation at the laboratory level can be achieved efficiently and these improvements can directly impact and shape testing and patient outcomes. Real-time testing […]

The ultimate aim of precision medicine is to treat a patient with a drug that perfectly fits their disease and genetic make-up. It is intended to target the disease or tumor, acting on that part of the body alone and causing minimal side effects. It’s a wonderful concept and we are beginning to see this […]

Think of all the rules you need to follow, and all the steps you need to take, in order to make a successful life partnership flourish. In precision medicine, where patients get diagnostic tests to establish their suitability for a specific therapy, getting the partnership right between diagnostic and pharmaceutical companies is similarly complex and […]

During the last few years there has been intense debate about the biomarker PD-L1. It has become a significant feature of precision medicine but its uptake in diagnostic testing has been affected by a number of factors such as availability in labs, confusion over testing options, the platforms required and the interpretation and reporting of results. It’s a situation Diaceutics […]

With another FDA approval for Merck’s Keytruda, this time for gastric cancer, we see the onward march of PD-L1 therapy development. This time the therapy has been approved alongside the Agilent Technology companion diagnostic 22C3 pharmDx kit to test for PD-L1 IHC. When a therapy is approved for a new indication, pharma companies can benefit from an in-depth landscape analysis of a particular companion diagnostic market in order to understand the testing options for an advanced disease, the sample availability, the […]

The diagnostic approval process is an essential part of the commercialization and regulation of novel tests. Tests have to be approved for use by regulatory authorities and getting that approval can be a lengthy and complex process. This is made more complicated by the fact that different global regions enforce their own processes, and these […]